Icotinib as Adjuvant Therapy Compared With Standard Chemotherapy in Stage II-IIIA NSCLC With EGFR-mutation

Clinical trial NCT02448797 · UNKNOWN

Trial details

NCT number: NCT02448797
Sponsor: Betta Pharmaceuticals Co., Ltd.
Status: UNKNOWN
Phase: Phase 3
Study type: INTERVENTIONAL

Non-small Cell Lung Cancer

Start date: 2015-06-08
Primary completion: 2022-06-30
Enrollment: 320

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.